Portuguese biotech company SilicoLife secures Series A investment of up to $10.5 million
In Portugal, SilicoLife said it concluded the first of two Series A rounds fundraising to the tune of $5.23 million, covered in its entirety by funds managed by venture capital firm BlueCrow .
BlueCrow is committed to securing a second, equally sizable, round of investment in SilicoLife. The two rounds of investment are aimed at supporting the development and evolution of the company’s business model over the next 3 to 5 years.
SilicoLife combines AI and Biology to further the sustainable production of various ingredients, using precision fermentation and microorganism engineering.
“Fermentation is the manufacturing technology of the future. We are leveraging our technological expertise and experience in developing new biological processes to address the currently unmet needs of the high-growth supplement industry. The cooperation between SilicoLife and BlueCrow combines our recognized expertise in R&D with the financial strength and scope of the funds managed by BlueCrow to scale and potentiate a knowledge-based company,” Simão Soares, SilicoLife CEO, said.
Category: SAF
